NCT00577629 - Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 18, 2005

Primary Completion Date

April 8, 2012

Study Completion Date

November 3, 2016

Conditions

Lymphoma, B-Cell

Interventions

DRUG

cyclophosphamide

1.5g/m2 IV over 1 hour on days 1-4 of induction for a total dose of 6.0g/m2

DRUG

etoposide

300mg/m2 IV over 1 hour every 12 on days 1-3 of induction for a total dose of 1.8 g/m2.

DRUG

rituximab

375mg/m2 each week x 4 weeks of induction, beginning on day 1

DRUG

cytarabine

3g/m2 IV over 1 hour every 12 during consolidation for a total of 8 doses

DRUG

doxorubicin

45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation

DRUG

tositumomab

450mg unlabeled tositumomab over 1 hour, followed by 5 millicurie (mCi) Iodine I-131 labeled tositumomab over 20 minutes on day 0. Therapeutic dose of labeled tositumomab will be administered on day 15.

Trial Locations (1)

27710

Duke University Medical Center, Durham